

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-98)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	10/622,769
Filing Date	July 21, 2003
First Named Inventor	Emir
Group Art Unit	
Examiner Name	
Attorney Docket Number	109536.182

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		Shua-Haim et al, Annals of Long-Term Care, Volume 7, No. 2 (February 1999) (5 pages).	
ESO		Pfizer Press Release dated August 30, 2000 (4 pages).	
ESO		Pfizer Press Release dated August 28, 2001 (5 pages).	
ESO		Eisai Press Release dated April 4, 2003 (5 pages).	
ESO		Feldman et al, Neurology, 54(Suppl. 3):A469 (Abstract No. S79.003) (April 2000).	
ESO		Feldman et al, Neurology, 57:613-620 (2001).	
ESO		The Pharmaceutical Journal, 267:376 (September 22, 2001).	
ESO		Burns et al, Dementia and Geriatric Cognitive Disorders, 10:237-244 (1999).	
ESO		Gauthier et al, International Psychogeriatrics, 14(4):389-404 (December 2002).	
ESO		Geldmacher, Comprehensive Therapy, 23(7):492-493 (1997).	
ESO		Rogers et al, Arch. Intern. Med., 158:1021-1031 (1998).	

Examiner
Signature

/Eric Olson/

Date
Considered

05/04/2006


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-86)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/622,769
Filing Date	July 21, 2003
First Named Inventor	Emir
Group Art Unit	
Examiner Name	
Attorney Docket Number	109536.182

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ESO		Perry et al, The Lancet, page 189 (January 22, 1977).	
ESO		Homma et al, Dementia and Geriatric Cognitive Disorders, 11:299-313 (2000).	
ESO		Doody, Gerontology, 45(suppl. 1):23-32 (1999).	
ESO		Doody et al, Arch. Neurol., 58:427-433 (March 2001).	
ESO		Onofrj et al, Clinical Neuropharmacology, 25(4):207-215 (2002).	

Examiner Signature	/Eric Olson/	Date Considered	05/04/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

(PTO-1449)

ATTY. DOCKET NO.
109536.182

SERIAL NO.
unassigned

APPLICANT
Birol EMIR et al.

FILING DATE
Herewith

GROUP

[illegible]

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

ESO	Shua-Haim, J. R., MD, FACP, AGSF, Vered Shua-Haim, RN, BSN, Mildred Sabo, MD and J. S. Ross, MD, FACP, AGSF, "Case Report: Donepezil in the Treatment of Advanced Alzheimer's Disease," Volume 7, Number 2, February 1999, 5 pages.

EXAMINER

/Eric Olson/

DATE CONSIDERED

05/02/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.